Here’s the latest instalment of our news updates from Blackford Platform Partners.
Medical imaging software firm
Resonance Health has submitted its 510(k) application for regulatory clearance by the US FDA for its newly developed AI solution. HepaFat-AI is a fully automated AI software tool that measures a patient’s volumetric liver fat fraction. It can be deployed in the cloud or on premises and can be integrated directly into existing radiology workflows. In our last update, medical 3D printing specialist
axial3D revealed it was pivoting to work on COVID-19 solutions, including reusable face shields. The company tells us it has now shipped more than 20,000 shields to frontline healthcare workers. Amongst a range of other COVID-19 projects, axial3D is now producing up to 10,000 swabs per day, which are used for collecting samples to test for the virus, as well as producing connectors for scuba masks (which are being used as emergency respirators) and making parts for ventilators. Lung analysis firm
VIDA added an
extra $2 million to its Series C funding from a new investor, bringing the round up to $13 million. The company was also proud to be named
2020 Company of the Year by Frost and Sullivan in the area of global radiology AI for lung care. VIDA’s CEO had a busy month, speaking at AuntMinnie’s
virtual conference, being awarded the
Joe Rosenfield Award by Next Level Ventures, and also
speaking to AIMed about AI's role in COVID-19. Our friends at
icometrix have also been busy,
securing CE clearance for its ico
lung solution, which offers
fast and objective quantification of lung pathology on chest CT scans in admitted COVID-19 patients. The company also launched ico
mpanion, a web app for remote monitoring of people with neurological conditions like MS. icometrix is
hosting a webinar on atrophy in MS on May 14
th. Medical diagnostic provider
MaxQ AI unveiled a powerful
new video that addresses the key question, “What is the cost of a missed intracranial hemorrhage (ICH)?” The company’s ACCIPIO platform uses AI for assessment of non-contrast head CT for intracranial hemorrhage (ICH) detection. The company also published a new testimonial from Dr Mark Delano at Michigan State University, who said, “We serve multiple hospitals where we may have several CT head cases with other stat exams to read – with no way of knowing what is the most acute without adding more radiologists… Having an intelligent agent prioritize these cases would increase safety, improve patient care, and inform staffing decisions.”
Stay tuned for more partner news next month!